ONCAlert | Upfront Therapy for mRCC
Videos  >  

Emerging Themes in Targeted Therapy Research for CLL

John F. Seymour, MBBS, PhD
Published Online:4:50 PM, Mon February 11, 2019


John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Cancer Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, discusses some emerging themes in research for targeted therapies as a treatment for patients with chronic lymphocytic leukemia (CLL).

Targeted agents are here to stay, says Seymour. These agents are more effective, safer, and are less genotoxic than treatment with chemoimmunotherapy.

For the majority of patients in subsets with CLL, these targeted agents will move to earlier lines of treatment. Seymour also says that combinations can achieve deeper responses and have become critical to enable time-limited therapy. Seymour emphasizes that time-limited therapy is where patients, prescribers, and health systems in the CLL space should move toward in the future.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.